Tackling seizures in patients with Alzheimer’s disease

References

• Murray CJL, Barber RM, Foreman KJ, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet. 2015;386(10009):2145–2191. doi: 10.1016/S0140-6736(15)61340-X
   PubMed Web of Science ®Google Scholar
• Perl DP. Neuropathology of Alzheimer’s disease. Mt Sinai J Med. 2010;77(1):32–42. doi: 10.1002/msj.20157
   PubMedGoogle Scholar
• Friedman D, Honig LS, Scarmeas N. Seizures and epilepsy in Alzheimer’s disease. CNS Neurosci Ther. 2012;18(4):285–294. doi: 10.1111/j.1755-5949.2011.00251.x
   PubMed Web of Science ®Google Scholar
• Scarmeas N, Honig LS, Choi H, et al. Seizures in Alzheimer disease: who, when, and how common? Arch Neurol. 2009;66(8):992–997. doi: 10.1001/archneurol.2009.130
   PubMedGoogle Scholar
• Zhao B, Shen L-X, Ou Y-N, et al. Risk of seizures and subclinical epileptiform activity in patients with dementia: a systematic review and meta-analysis. Ageing Res Rev. 2021;72:101478. doi: 10.1016/j.arr.2021.101478
   PubMed Web of Science ®Google Scholar
• Zawar I, Kapur J. Does Alzheimer’s disease with mesial temporal lobe epilepsy represent a distinct disease subtype? Alzheimer’s & dementia. Alzheimer’s Dementia. 2023;19(6):2697–2706. doi: 10.1002/alz.12943
   PubMedGoogle Scholar
• Tombini M, Assenza G, Ricci L, et al. Temporal lobe epilepsy and Alzheimer’s disease: from preclinical to clinical evidence of a strong Association. ADR. 2021;5(1):243–261. doi: 10.3233/ADR-200286
   Google Scholar
• Hesdorffer DC, Hauser WA, Annegers JF, et al. Dementia and adult-onset unprovoked seizures. Neurology. 1996;46(3):727–730. doi: 10.1212/WNL.46.3.727
   PubMed Web of Science ®Google Scholar
• Amatniek JC, Hauser WA, DelCastillo-Castaneda C, et al. Incidence and predictors of seizures in patients with Alzheimer’s disease. Epilepsia. 2006;47:867–872. doi: 10.1111/j.1528-1167.2006.00554.x
   PubMed Web of Science ®Google Scholar
• Johnson EL, Krauss GL, Kucharska-Newton A, et al. Dementia in late-onset epilepsy: the atherosclerosis risk in communities study. Neurology. 2020;95(24):e3248–e3256. doi: 10.1212/WNL.0000000000011080
   PubMed Web of Science ®Google Scholar
• Breteler MM, van Duijn CM, Chandra V, et al. Medical history and the risk of Alzheimer’s disease: a collaborative re-analysis of case-control studies. EURODEM risk factors research group. Int J Epidemiol. 1991;20 Suppl 2(Supplement 2):S36–42. doi: 10.1093/ije/20.Supplement_2.S36
   PubMedGoogle Scholar
• Johnson EL, Krauss GL, Lee AK, et al. Association between midlife risk factors and late-onset epilepsy: results from the atherosclerosis risk in communities study. JAMA Neurol. 2018;75(11):1375–1382. doi: 10.1001/jamaneurol.2018.1935
   PubMed Web of Science ®Google Scholar
• Cleary P, Shorvon S, Tallis R. Late-onset seizures as a predictor of subsequent stroke. Lancet. 2004;363(9416):1184–1186. doi: 10.1016/S0140-6736(04)15946-1
   PubMed Web of Science ®Google Scholar
• Wannamaker BB, Wilson DA, Malek AM, et al. Stroke after adult-onset epilepsy: a population-based retrospective cohort study. Epilepsy Behav. 2015;43:93–99. doi: 10.1016/j.yebeh.2014.11.028
   PubMed Web of Science ®Google Scholar
• Sillanpää M, Anttinen A, Rinne JO, et al. Childhood-onset epilepsy five decades later. A prospective population-based cohort study. Epilepsia. 2015;56(11):1774–1783. doi: 10.1111/epi.13187
   PubMed Web of Science ®Google Scholar
• Joutsa J, Rinne JO, Hermann B, et al. Association between childhood-onset epilepsy and amyloid burden 5 decades later. JAMA Neurol. 2017;74(5):583. doi: 10.1001/jamaneurol.2016.6091
   PubMed Web of Science ®Google Scholar
• Liu C-C, Liu C-C, Kanekiyo T, et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106–118. doi: 10.1038/nrneurol.2012.263
   PubMed Web of Science ®Google Scholar
• Thygesen LC, Gimsing L, Bautz A, et al. Chronic neurodegenerative illnesses and epilepsy in Danish Adventists and Baptists: a nationwide cohort study. JAD. 2017;56(4):1429–1435. doi: 10.3233/JAD-160710
   Google Scholar
• Forloni G, Balducci C, Perry G, et al. Alzheimer’s disease, Oligomers, and inflammation. Perry G, Avila J, Tabaton M, et al., editors. JAD. 2018;62(3):1261–1276. doi: 10.3233/JAD-170819
   Google Scholar
• Vezzani A, French J, Bartfai T, et al. The role of inflammation in epilepsy. Nat Rev Neurol. 2011;7(1):31–40. doi: 10.1038/nrneurol.2010.178
   PubMed Web of Science ®Google Scholar
• Vossel KA, Tartaglia MC, Nygaard HB, et al. Epileptic activity in Alzheimer’s disease: causes and clinical relevance. Lancet Neurol. 2017;16(4):311–322. doi: 10.1016/S1474-4422(17)30044-3
   PubMed Web of Science ®Google Scholar
• Noebels J. A perfect storm: converging paths of epilepsy and Alzheimer’s dementia intersect in the hippocampal formation. Epilepsia. 2011;52(Suppl 1):39–46. doi: 10.1111/j.1528-1167.2010.02909.x
   PubMedGoogle Scholar
• Cretin B, Sellal F, Philippi N, et al. Epileptic prodromal Alzheimer’s disease, a retrospective study of 13 new cases: expanding the spectrum of alzheimer’s disease to an epileptic variant? J Alzheimers Dis. 2016;52(3):1125–1133. doi: 10.3233/JAD-150096
   PubMed Web of Science ®Google Scholar
• Vossel KA, Beagle AJ, Rabinovici GD, et al. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 2013;70(9):1158–1166. doi: 10.1001/jamaneurol.2013.136
   PubMed Web of Science ®Google Scholar
• Palop JJ, Mucke L. Amyloid-β–induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks. Nat Neurosci. 2010;13(7):812–818. doi: 10.1038/nn.2583
   PubMed Web of Science ®Google Scholar
• Irizarry MC, Jin S, He F, et al. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch Neurol. 2012;69(3):368–372. doi: 10.1001/archneurol.2011.830
   PubMedGoogle Scholar
• Putcha D, Brickhouse M, O’Keefe K, et al. Hippocampal hyperactivation associated with cortical thinning in Alzheimer’s disease signature regions in non-demented elderly adults. J Neurosci. 2011;31(48):17680–17688. doi: 10.1523/JNEUROSCI.4740-11.2011
   PubMed Web of Science ®Google Scholar
• Zott B, Busche MA, Sperling RA, et al. What happens with the circuit in Alzheimer’s disease in mice and humans? Annu Rev Neurosci. 2018;41(1):277–297. doi: 10.1146/annurev-neuro-080317-061725
   PubMedGoogle Scholar
• Vossel KA, Ranasinghe KG, Beagle AJ, et al. Incidence and impact of subclinical epileptiform activity in Alzheimer’s disease: subclinical epileptiform activity in AD. Ann Neurol. 2016;80(6):858–870. doi: 10.1002/ana.24794
   PubMed Web of Science ®Google Scholar
• Feigin VL, Nichols E, Alam T, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18(5):459–480. doi: 10.1016/S1474-4422(18)30499-X
   PubMed Web of Science ®Google Scholar
• Hauser WA, Annegers JF, Kurland LT. Incidence of Epilepsy and Unprovoked Seizures in Rochester, Minnesota: 1935–1984. Epilepsia. 1993;34(3):453–458. doi: 10.1111/j.1528-1157.1993.tb02586.x
   PubMed Web of Science ®Google Scholar
• Neri S, Mastroianni G, Gardella E, et al. Epilepsy in neurodegenerative diseases. Epileptic Disord. 2022;24(2):249–273. doi: 10.1684/epd.2021.1406
   PubMed Web of Science ®Google Scholar
• Mendez MF, Lim GTH. Seizures in Elderly Patients with Dementia: Epidemiology and Management. Drugs Aging. 2003;20(11):791–803. doi: 10.2165/00002512-200320110-00001
   PubMed Web of Science ®Google Scholar
• Asadollahi M, Atazadeh M, Noroozian M. Seizure in Alzheimer’s Disease: An Underestimated Phenomenon. Am J Alzheimers Dis Other Demen. 2019;34(2):81–88. doi: 10.1177/1533317518813551
   PubMed Web of Science ®Google Scholar
• Cook M, Baker N, Lanes S, et al. Incidence of stroke and seizure in Alzheimer’s disease dementia. Age Ageing. 2015;44:695–699. doi: 10.1093/ageing/afv061
   PubMed Web of Science ®Google Scholar
• Samson WN, van Duijn CM, Hop WC, et al. Clinical features and mortality in patients with early-onset Alzheimer’s disease. Eur Neurol. 1996;36(2):103–106. doi: 10.1159/000117218
   PubMed Web of Science ®Google Scholar
• Amatniek JC, Hauser WA, DelCastillo-Castaneda C, et al. Incidence and predictors of seizures in patients with Alzheimer’s disease. 2006;47:6. doi: 10.1111/j.1528-1167.2006.00554.x
   Google Scholar
• Larner AJ. Presenilin-1 mutation Alzheimer’s disease: a genetic epilepsy syndrome? Epilepsy Behav. 2011;21(1):20–22. doi: 10.1016/j.yebeh.2011.03.022
   PubMed Web of Science ®Google Scholar
• Cabrejo L, Guyant-Maréchal L, Laquerrière A, et al. Phenotype associated with APP duplication in five families. Brain. 2006;129(11):2966–2976. doi: 10.1093/brain/awl237
   PubMed Web of Science ®Google Scholar
• Jayadev S, Leverenz JB, Steinbart E, et al. Alzheimer’s disease phenotypes and genotypes associated with mutations in presenilin 2. Brain. 2010;133(4):1143–1154. doi: 10.1093/brain/awq033
   PubMed Web of Science ®Google Scholar
• Lai F, Williams RS. A prospective study of Alzheimer disease in Down syndrome. Arch Neurol. 1989;46(8):849–853. doi: 10.1001/archneur.1989.00520440031017
   PubMedGoogle Scholar
• Möller JC, Hamer HM, Oertel WH, et al. Late-onset myoclonic epilepsy in Down’s syndrome (LOMEDS). Seizure. 2001;10(4):303–305. doi: 10.1053/seiz.2000.0500
   PubMed Web of Science ®Google Scholar
• Beagle AJ, Darwish SM, Ranasinghe KG, et al. Relative Incidence of seizures and myoclonus in Alzheimer’s disease, dementia with Lewy Bodies, and Frontotemporal dementia. Cretin B, editor. JAD. 2017;60(1):211–223. doi: 10.3233/JAD-170031
   Google Scholar
• Chen J-Y, Stern Y, Sano M, et al. Cumulative risks of developing extrapyramidal signs, psychosis, or myoclonus in the course of Alzheimer’s disease. Arch Neurol. 1991;48(11):1141–1143. doi: 10.1001/archneur.1991.00530230049020
   PubMedGoogle Scholar
• Ugawa Y, Kohara N, Hirasawa H, et al. Myoclonus in Alzheimer’s disease. J Neurol. 1987;235(2):90–94. doi: 10.1007/BF00718016
   PubMedGoogle Scholar
• Hallett M, Wilkins DE. Myoclonus in Alzheimer’s disease and minipolymyoclonus. Adv Neurol. 1986;43:399–405.
   PubMedGoogle Scholar
• Rao SC, Dove G, Cascino GD, et al. Recurrent seizures in patients with dementia: frequency, seizure types, and treatment outcome. Epilepsy Behav. 2009;14(1):118–120. doi: 10.1016/j.yebeh.2008.08.012
   PubMed Web of Science ®Google Scholar
• Zarea A, Charbonnier C, Rovelet-Lecrux A, et al. Seizures in dominantly inherited Alzheimer disease. Neurology. 2016;87(9):912–919. doi: 10.1212/WNL.0000000000003048
   PubMed Web of Science ®Google Scholar
• Sarkis RA, Dickerson BC, Cole AJ, et al. Clinical and neurophysiologic characteristics of unprovoked seizures in patients diagnosed with dementia. JNP. 2016;28(1):56–61. doi: 10.1176/appi.neuropsych.15060143
   Google Scholar
• Lanz M, Oehl B, Brandt A, et al. Seizure induced cardiac asystole in epilepsy patients undergoing long term video-EEG monitoring. Seizure. 2011;20(2):167–172. doi: 10.1016/j.seizure.2010.11.017
   PubMed Web of Science ®Google Scholar
• Subota A, Jetté N, Josephson CB, et al. Risk factors for dementia development, frailty, and mortality in older adults with epilepsy – a population-based analysis. Epilepsy Behav. 2021;120:108006. doi: 10.1016/j.yebeh.2021.108006
   PubMed Web of Science ®Google Scholar
• Werhahn KJ Epilepsy in the elderly. Deutsches Ärzteblatt international [Internet]. 2009 [cited 2023 Jun 24]. Available from: https://www.aerzteblatt.de/10.3238/arztebl.2009.0135.
   Google Scholar
• Brodie MJ, Elder AT, Kwan P. Epilepsy in later life. Lancet Neurol. 2009;8(11):1019–1030. doi: 10.1016/S1474-4422(09)70240-6
   PubMed Web of Science ®Google Scholar
• Epilepsy Study Group of the Italian Neurological Society, Ricci L, Boscarino M, et al. Clinical utility of home videos for diagnosing epileptic seizures: a systematic review and practical recommendations for optimal and safe recording. Neurol Sci. 2021;42(4):1301–1309.
   PubMed Web of Science ®Google Scholar
• Veran O, Kahane P, Thomas P, et al. De Novo epileptic confusion in the elderly: A 1-year prospective study: De Novo epileptic confusion in the elderly. Epilepsia. 2009;51(6):1030–1035. doi: 10.1111/j.1528-1167.2009.02410.x
   PubMed Web of Science ®Google Scholar
• Rabinowicz AL, Starkstein SE, Leiguarda RC, et al. Transient Epileptic Amnesia in Dementia: A Treatable Unrecognized Cause of Episodic Amnestic Wandering. Alzheimer Dis Associated Disorde. 2000;14(4):231–233. doi: 10.1097/00002093-200010000-00008
   PubMed Web of Science ®Google Scholar
• Cretin B, Philippi N, Sellal F, et al. Can the syndrome of transient epileptic amnesia be the first feature of Alzheimer’s disease? Seizure. 2014;23(10):918–920. doi: 10.1016/j.seizure.2014.07.008
   PubMed Web of Science ®Google Scholar
• Gallassi R. Epileptic Amnesic syndrome: an update and further considerations. Epilepsia. 2006;47(s2):103–105. doi: 10.1111/j.1528-1167.2006.00704.x
   PubMedGoogle Scholar
• Palop JJ, Chin J, Roberson ED, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer’s disease. Neuron. 2007;55:697–711. doi: 10.1016/j.neuron.2007.07.025
   PubMed Web of Science ®Google Scholar
• Cirrito JR, Yamada KA, Finn MB, et al. Synaptic activity regulates interstitial fluid amyloid-β levels in vivo. Neuron. 2005;48(6):913–922. doi: 10.1016/j.neuron.2005.10.028
   PubMed Web of Science ®Google Scholar
• Reyes-Marin KE, Nuñez A. Seizure susceptibility in the APP/PS1 mouse model of Alzheimer’s disease and relationship with amyloid β plaques. Brain Res. 2017;1677:93–100. doi: 10.1016/j.brainres.2017.09.026
   PubMed Web of Science ®Google Scholar
• Harris SS, Wolf F, De Strooper B, et al. Tipping the scales: peptide-dependent dysregulation of neural circuit dynamics in Alzheimer’s disease. Neuron. 2020;107(3):417–435. doi: 10.1016/j.neuron.2020.06.005
   PubMed Web of Science ®Google Scholar
• Rodriguez GA, Barrett GM, Duff KE, et al. Chemogenetic attenuation of neuronal activity in the entorhinal cortex reduces Aβ and tau pathology in the hippocampus. PLoS Biol. 2020;18(8):e3000851. doi: 10.1371/journal.pbio.3000851
   PubMed Web of Science ®Google Scholar
• Saito Y, Inoue T, Zhu G, et al. Hyperpolarization-activated cyclic nucleotide gated channels: a potential molecular link between epileptic seizures and Aβ generation in Alzheimer’s disease. Mol Neurodegener. 2012;7(1):50. doi: 10.1186/1750-1326-7-50
   PubMedGoogle Scholar
• Gourmaud S, Shou H, Irwin DJ, et al. Alzheimer-like amyloid and tau alterations associated with cognitive deficit in temporal lobe epilepsy. Brain. 2020;143(1):191–209. doi: 10.1093/brain/awz381
   PubMedGoogle Scholar
• Costa C, Romoli M, Liguori C, et al. Alzheimer’s disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology. Neurobiol Aging. 2019;73:61–67. doi: 10.1016/j.neurobiolaging.2018.09.006
   PubMed Web of Science ®Google Scholar
• Decker JM, Krüger L, Sydow A, et al. The tau/A152T mutation, a risk factor for frontotemporal-spectrum disorders, leads to NR 2B receptor-mediated excitotoxicity. EMBO Rep. 2016;17(4):552–569. doi: 10.15252/embr.201541439
   PubMed Web of Science ®Google Scholar
• Ittner LM, Ke YD, Delerue F, et al. Dendritic function of tau Mediates amyloid-β Toxicity in Alzheimer’s disease mouse models. Cell. 2010;142(3):387–397. doi: 10.1016/j.cell.2010.06.036
   PubMed Web of Science ®Google Scholar
• Holth JK, Bomben VC, Reed JG, et al. Tau loss Attenuates neuronal network hyperexcitability in mouse and Drosophila genetic models of epilepsy. J Neurosci. 2013;33(4):1651–1659. doi: 10.1523/JNEUROSCI.3191-12.2013
   PubMed Web of Science ®Google Scholar
• Wu JW, Hussaini SA, Bastille IM, et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat Neurosci. 2016;19(8):1085–1092. doi: 10.1038/nn.4328
   PubMed Web of Science ®Google Scholar
• Roberson ED, Halabisky B, Yoo JW, et al. Amyloid-β/Fyn–Induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer’s disease. J Neurosci. 2011;31(2):700–711. doi: 10.1523/JNEUROSCI.4152-10.2011
   PubMed Web of Science ®Google Scholar
• DeVos SL, Goncharoff DK, Chen G, et al. Antisense reduction of tau in adult mice protects against seizures. J Neurosci. 2013;33(31):12887–12897. doi: 10.1523/JNEUROSCI.2107-13.2013
   PubMed Web of Science ®Google Scholar
• Tai XY, Koepp M, Duncan JS, et al. Hyperphosphorylated tau in patients with refractory epilepsy correlates with cognitive decline: a study of temporal lobe resections. Brain. 2016;139(9):2441–2455. doi: 10.1093/brain/aww187
   PubMedGoogle Scholar
• Tábuas-Pereira M, Durães J, Lopes J, et al. Increased CSF tau is associated with a higher risk of seizures in patients with Alzheimer’s disease. Epilepsy Behav. 2019;98:207–209. doi: 10.1016/j.yebeh.2019.06.033
   PubMed Web of Science ®Google Scholar
• Hickman LB, Stern JM, Silverman DHS, et al. Clinical, imaging, and biomarker evidence of amyloid- and tau-related neurodegeneration in late-onset epilepsy of unknown etiology. Front Neurol. 2023;14:1241638. doi: 10.3389/fneur.2023.1241638
   PubMed Web of Science ®Google Scholar
• Jack CR, Bennett DA, Blennow K, et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539–547. doi: 10.1212/WNL.0000000000002923
   PubMed Web of Science ®Google Scholar
• Ehlers MD. Peripheral activity and central substrates of BACE1: therapeutic implications for Alzheimer’s disease. Biol Psychiatry. 2018;83(5):393–394. doi: 10.1016/j.biopsych.2017.12.005
   PubMed Web of Science ®Google Scholar
• Hu X, Zhou X, He W, et al. BACE1 deficiency causes altered neuronal activity and neurodegeneration. J Neurosci. 2010;30(26):8819–8829. doi: 10.1523/JNEUROSCI.1334-10.2010
   PubMed Web of Science ®Google Scholar
• Mazdeh M, Komaki A, Omrani MD, et al. Expression analysis of beta-secretase 1 (BACE1) and its naturally occurring antisense (BACE1-AS) in blood of epileptic patients. Neurol Sci. 2018;39(9):1565–1569. doi: 10.1007/s10072-018-3458-3
   PubMed Web of Science ®Google Scholar
• Sweeney MD, Sagare AP, Zlokovic BV. Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14(3):133–150. doi: 10.1038/nrneurol.2017.188
   PubMed Web of Science ®Google Scholar
• Hodges SL, Lugo JN. Therapeutic role of targeting mTOR signaling and neuroinflammation in epilepsy. Epilepsy Res. 2020;161:106282. doi: 10.1016/j.eplepsyres.2020.106282
   PubMed Web of Science ®Google Scholar
• Heneka MT, Carson MJ, Khoury JE, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14(4):388–405. doi: 10.1016/S1474-4422(15)70016-5
   PubMed Web of Science ®Google Scholar
• Aboud O, Mrak RE, Boop FA, et al. Epilepsy: neuroinflammation, neurodegeneration, and APOE genotype. acta neuropathol commun. Acta Neuropathol Commun. 2013;1(1):41. doi: 10.1186/2051-5960-1-41
   PubMedGoogle Scholar
• Ramos B, Baglietto-Vargas D, Del Rio JC, et al. Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1×APP transgenic model of Alzheimer’s disease. Neurobiol Aging. 2006;27(11):1658–1672. doi: 10.1016/j.neurobiolaging.2005.09.022
   PubMed Web of Science ®Google Scholar
• Iascone DM, Li Y, Sümbül U, et al. Whole-neuron synaptic mapping reveals spatially precise excitatory/inhibitory balance limiting dendritic and somatic spiking. Neuron. 2020;106(4):566–578.e8. doi: 10.1016/j.neuron.2020.02.015
   PubMed Web of Science ®Google Scholar
• Guzmán B C-F, Vinnakota C, Govindpani K, et al. The GABAergic system as a therapeutic target for Alzheimer’s disease. Journal Of Neurochemistry. 2018;146(6):649–669. doi: 10.1111/jnc.14345
   PubMed Web of Science ®Google Scholar
• Lauterborn JC, Scaduto P, Cox CD, et al. Increased excitatory to inhibitory synaptic ratio in parietal cortex samples from individuals with Alzheimer’s disease. Nat Commun. 2021;12(1):2603. doi: 10.1038/s41467-021-22742-8
   PubMed Web of Science ®Google Scholar
• Huijbers W, Mormino EC, Schultz AP, et al. Amyloid-β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. Brain. 2015;138(4):1023–1035. doi: 10.1093/brain/awv007
   PubMedGoogle Scholar
• Bakker A, Albert MS, Krauss G, et al. Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance. NeuroImage Clin. 2015;7:688–698. doi: 10.1016/j.nicl.2015.02.009
   PubMed Web of Science ®Google Scholar
• Sperling RA, Laviolette PS, O’Keefe K, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63(2):178–188. doi: 10.1016/j.neuron.2009.07.003
   PubMed Web of Science ®Google Scholar
• Di Lazzaro V, Rothwell J, Capogna M. Noninvasive stimulation of the human brain: activation of multiple cortical circuits. Neuroscientist. 2018;24(3):246–260. doi: 10.1177/1073858417717660
   PubMed Web of Science ®Google Scholar
• de Goede AA, Ter Braack EM, van Putten MJAM. Single and paired pulse transcranial magnetic stimulation in drug naïve epilepsy. Clin Neurophysiol. 2016;127(9):3140–3155. doi: 10.1016/j.clinph.2016.06.025
   PubMed Web of Science ®Google Scholar
• Cantone M, Di Pino G, Capone F, et al. The contribution of transcranial magnetic stimulation in the diagnosis and in the management of dementia. Clin Neurophysiol. 2014;125(8):1509–1532. doi: 10.1016/j.clinph.2014.04.010
   PubMed Web of Science ®Google Scholar
• Di Lazzaro V, Bella R, Benussi A, et al. Diagnostic contribution and therapeutic perspectives of transcranial magnetic stimulation in dementia. Clin Neurophysiol. 2021;132(10):2568–2607. doi: 10.1016/j.clinph.2021.05.035
   PubMed Web of Science ®Google Scholar
• Horváth A, Szűcs A, Hidasi Z, et al. Prevalence, semiology, and risk factors of epilepsy in Alzheimer’s disease: an ambulatory EEG study. JAD. 2018;63(3):1045–1054. doi: 10.3233/JAD-170925
   Google Scholar
• Liedorp M, Stam CJ, van der Flier WM, et al. Prevalence and clinical significance of epileptiform EEG discharges in a large memory clinic cohort. Dement Geriatr Cognit Disord. 2010;29(5):432–437. doi: 10.1159/000278620
   PubMed Web of Science ®Google Scholar
• Brunetti V, D’Atri A, Della Marca G, et al. Subclinical epileptiform activity during sleep in Alzheimer’s disease and mild cognitive impairment. Clin Neurophysiol. 2020;131(5):1011–1018. doi: 10.1016/j.clinph.2020.02.015
   PubMed Web of Science ®Google Scholar
• Lam AD, Sarkis RA, Pellerin KR, et al. Association of epileptiform abnormalities and seizures in Alzheimer disease. Neurology. 2020;95(16):e2259–e2270. doi: 10.1212/WNL.0000000000010612
   PubMed Web of Science ®Google Scholar
• Ung H, Cazares C, Nanivadekar A, et al. Interictal epileptiform activity outside the seizure onset zone impacts cognition. Brain. 2017;140(8):2157–2168. doi: 10.1093/brain/awx143
   PubMedGoogle Scholar
• Krauss GL, Summerfield M, Brandt J, et al. Mesial temporal spikes interfere with working memory. Neurology. 1997;49(4):975–980. doi: 10.1212/WNL.49.4.975
   PubMed Web of Science ®Google Scholar
• Aldenkamp AP, Arends J. Effects of epileptiform EEG discharges on cognitive function: is the concept of “transient cognitive impairment” still valid? Epilepsy Behav. 2004;5(Suppl 1):S25–34. doi: 10.1016/j.yebeh.2003.11.005
   PubMedGoogle Scholar
• Aldenkamp AP, Arends J, Verspeek S, et al. The cognitive impact of epileptiform EEG-discharges; relationship with type of cognitive task. Child Neuropsychol. 2004;10(4):297–305. doi: 10.1080/09297040490909341
   PubMed Web of Science ®Google Scholar
• Kleen JK, Scott RC, Holmes GL, et al. Hippocampal interictal epileptiform activity disrupts cognition in humans. Neurology. 2013;81(1):18–24. doi: 10.1212/WNL.0b013e318297ee50
   PubMed Web of Science ®Google Scholar
• Lam AD, Deck G, Goldman A, et al. Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer’s disease. Nat Med. 2017;23(6):678–680. doi: 10.1038/nm.4330
   PubMed Web of Science ®Google Scholar
• Bootsma HP, Ricker L, Hekster YA, et al. The impact of side effects on long-term retention in three new antiepileptic drugs. Seizure. 2009;18(5):327–331. doi: 10.1016/j.seizure.2008.11.006
   PubMed Web of Science ®Google Scholar
• Mula M, Trimble MR. Antiepileptic drug-induced cognitive adverse effects: potential mechanisms and contributing factors. CNS Drugs. 2009;23(2):121–137. doi: 10.2165/00023210-200923020-00003
   PubMed Web of Science ®Google Scholar
• Picton JD, Marino AB, Nealy KL. Benzodiazepine use and cognitive decline in the elderly. Am J Health Syst Pharm. 2018;75(1):e6–e12. doi: 10.2146/ajhp160381
   PubMed Web of Science ®Google Scholar
• Aldenkamp AP. Effects of antiepileptic drugs on cognition. Epilepsia. 2001;42(s1):46–49. doi: 10.1046/j.1528-1157.2001.00516.x
   PubMedGoogle Scholar
• Hessen E, Lossius MI, Reinvang I, et al. Influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy: COGNITIVE INFLUENCE of MAJOR AEDS. Epilepsia. 2006;47(12):2038–2045. doi: 10.1111/j.1528-1167.2006.00805.x
   PubMed Web of Science ®Google Scholar
• Gomer B, Wagner K, Frings L, et al. The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate. Epilepsy Behav. 2007;10(3):486–494. doi: 10.1016/j.yebeh.2007.02.007
   PubMed Web of Science ®Google Scholar
• Ferrendelli JA, French J, Leppik I, et al. Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial. Epilepsy Behav. 2003;4(6):702–709. doi: 10.1016/j.yebeh.2003.09.007
   PubMed Web of Science ®Google Scholar
• Cumbo E, Ligori LD. Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer’s disease. Epilepsy Behav. 2010;17(4):461–466. doi: 10.1016/j.yebeh.2010.01.015
   PubMed Web of Science ®Google Scholar
• Musaeus CS, Shafi MM, Santarnecchi E, et al. Levetiracetam alters oscillatory connectivity in Alzheimer’s disease. JAD. 2017;58(4):1065–1076. doi: 10.3233/JAD-160742
   Google Scholar
• Ricci L, Assenza G, Pulitano P, et al. Measuring the effects of first antiepileptic medication in temporal lobe epilepsy: predictive value of quantitative-EEG analysis. Clin Neurophysiol. 2021;132(1):25–35. doi: 10.1016/j.clinph.2020.10.020
   PubMed Web of Science ®Google Scholar
• Cretin B. Pharmacotherapeutic strategies for treating epilepsy in patients with Alzheimer’s disease. Expert Opin Pharmacother. 2018;19(11):1201–1209. doi: 10.1080/14656566.2018.1496237
   PubMed Web of Science ®Google Scholar
• Bakker A, Krauss GL, Albert MS, et al. Reduction of hippocampal hyperactivity Improves cognition in amnestic mild cognitive impairment. Neuron. 2012;74(3):467–474. doi: 10.1016/j.neuron.2012.03.023
   PubMed Web of Science ®Google Scholar
• Labiner DM, Ettinger AB, Fakhoury TA, et al. Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy. Epilepsia. 2009;50(3):434–442. doi: 10.1111/j.1528-1167.2008.01792.x
   PubMed Web of Science ®Google Scholar
• Ng B, Camacho A, Bardwell W, et al. Lamotrigine for agitation in older patients with dementia. IPG. 2009;21(1):207. doi: 10.1017/S1041610208007898
   Google Scholar
• Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology. 2005;64(11):1868–1873. doi: 10.1212/01.WNL.0000167384.68207.3E
   PubMed Web of Science ®Google Scholar
• Bainbridge J, De Backer M, Eckhardt K, et al. Safety and tolerability of lacosamide monotherapy in the elderly: a subgroup analysis from lacosamide trials in diabetic neuropathic pain. Epilepsia Open. 2017;2(4):415–423. doi: 10.1002/epi4.12079
   PubMedGoogle Scholar
• Bang SR, Ambavade SD, Jagdale PG, et al. Lacosamide reduces HDAC levels in the brain and improves memory: potential for treatment of Alzheimer’s disease. Pharmacol Biochem Behav. 2015;134:65–69. doi: 10.1016/j.pbb.2015.04.011
   PubMed Web of Science ®Google Scholar
• Witt J-A, Helmstaedter C. The impact of perampanel on cognition: a systematic review of studies employing standardized tests in patients with epilepsy. Seizure. 2022;94:107–111. doi: 10.1016/j.seizure.2021.12.001
   PubMed Web of Science ®Google Scholar
• Yue X, Liu X-M, Chen J, et al. The efficacy and cognitive impact of perampanel monotherapy in patients with self-limited epilepsy with centrotemporal spikes: a retrospective analysis. Neuropsychiatr Dis Treat. 2023;19:1263–1271. doi: 10.2147/NDT.S410858
   PubMed Web of Science ®Google Scholar
• Witt J-A, Elger CE, Helmstaedter C. Short-term and longer-term effects of brivaracetam on cognition and behavior in a naturalistic clinical setting—preliminary data. Seizure. 2018;62:49–54. doi: 10.1016/j.seizure.2018.09.016
   PubMed Web of Science ®Google Scholar
• Li K, Hsu C, Yang Y. A review of cognitive and behavioral outcomes of Brivaracetam. The Kaohsiung J Med Scie. 2023;39(2):104–114. doi: 10.1002/kjm2.12648
   PubMed Web of Science ®Google Scholar
• Bellingacci L, Tallarico M, Mancini A, et al. Non-competitive AMPA glutamate receptors antagonism by perampanel as a strategy to counteract hippocampal hyper-excitability and cognitive deficits in cerebral amyloidosis. Neuropharmacology. 2023;225:109373. doi: 10.1016/j.neuropharm.2022.109373
   PubMed Web of Science ®Google Scholar
• Nygaard HB, Kaufman AC, Sekine-Konno T, et al. Brivaracetam, but not ethosuximide, reverses memory impairments in an Alzheimer’s disease mouse model. Alz Res Therapy. 2015;7(1):25. doi: 10.1186/s13195-015-0110-9
   PubMedGoogle Scholar
• Schuetz E, Wagner K, Metternich B, et al. Effects of cenobamate on cognitive performance of epilepsy patients. Seizure. 2022;102:129–133. doi: 10.1016/j.seizure.2022.10.004
   PubMed Web of Science ®Google Scholar
• Lutz MT, Helmstaedter C. EpiTrack: tracking cognitive side effects of medication on attention and executive functions in patients with epilepsy. Epilepsy Behav. 2005;7(4):708–714. doi: 10.1016/j.yebeh.2005.08.015
   PubMed Web of Science ®Google Scholar
• Janssen S, Bloem BR, van de Warrenburg BP. The clinical heterogeneity of drug-induced myoclonus: an illustrated review. J Neurol. 2017;264(8):1559–1566. doi: 10.1007/s00415-016-8357-z
   PubMed Web of Science ®Google Scholar
• De Simone R, Puig XS, Gélisse P, et al. Senile myoclonic epilepsy: delineation of a common condition associated with Alzheimer’s disease in down syndrome. Seizure. 2010;19(7):383–389. doi: 10.1016/j.seizure.2010.04.008
   PubMed Web of Science ®Google Scholar
• Sanchez PE, Zhu L, Verret L, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model. Proc Natl Acad Sci U S A. 2012;109(42):E2895–2903. doi: 10.1073/pnas.1121081109
   PubMed Web of Science ®Google Scholar
• Zhang M-Y, Zheng C-Y, Zou M-M, et al. Lamotrigine attenuates deficits in synaptic plasticity and accumulation of amyloid plaques in APP/PS1 transgenic mice. Neurobiol Aging. 2014;35(12):2713–2725. doi: 10.1016/j.neurobiolaging.2014.06.009
   PubMed Web of Science ®Google Scholar
• Um JW, Nygaard HB, Heiss JK, et al. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci. 2012;15(9):1227–1235. doi: 10.1038/nn.3178
   PubMed Web of Science ®Google Scholar
• Shi J-Q, Wang B-R, Tian Y-Y, et al. Antiepileptics topiramate and levetiracetam alleviate behavioral deficits and reduce neuropathology in APPswe/PS1dE9 transgenic mice. CNS Neurosci Ther. 2013;19(11):871–881. doi: 10.1111/cns.12144
   PubMed Web of Science ®Google Scholar
• Corbett BF, You JC, Zhang X, et al. Δfosb Regulates Gene expression and cognitive dysfunction in a mouse model of Alzheimer’s disease. Cell Rep. 2017;20(2):344–355. doi: 10.1016/j.celrep.2017.06.040
   PubMed Web of Science ®Google Scholar
• Yassa MA, Stark SM, Bakker A, et al. High-resolution structural and functional MRI of hippocampal CA3 and dentate gyrus in patients with amnestic mild cognitive impairment. Neuroimage. 2010;51(3):1242–1252. doi: 10.1016/j.neuroimage.2010.03.040
   PubMed Web of Science ®Google Scholar
• Lippa CF, Rosso A, Hepler M, et al. Levetiracetam: A Practical Option for Seizure Management in Elderly Patients With Cognitive Impairment. Am J Alzheimers Dis Other Demen. 2010;25(2):149–154. doi: 10.1177/1533317508325095
   PubMed Web of Science ®Google Scholar
• Vossel K, Ranasinghe KG, Beagle AJ, et al. Effect of Levetiracetam on cognition in patients with Alzheimer disease with and without epileptiform activity: a randomized clinical trial. JAMA Neurol. 2021;78(11):1345. doi: 10.1001/jamaneurol.2021.3310
   PubMed Web of Science ®Google Scholar
• Sen A, Akinola M, Tai XY, et al. An Investigation of Levetiracetam in Alzheimer’s Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study. Trials. 2021;22(1):508. doi: 10.1186/s13063-021-05404-4
   PubMedGoogle Scholar
• Tekin S, Aykut-Bingöl C, Tanridağ T, et al. Antiglutamatergic therapy in Alzheimer’s disease–effects of lamotrigine. Short communication. J Neural Transm (Vienna). 1998;105(2–3):295–303. doi: 10.1007/s007020050059
   PubMed Web of Science ®Google Scholar
• Hautecloque-Raysz G, Sellal F, Bousiges O, et al. Epileptic prodromal Alzheimer’s disease treated with antiseizure medications: medium-term outcome of seizures and cognition. J Alzheimers Dis. 2023;94(3):1057–1074. doi: 10.3233/JAD-221197
   PubMed Web of Science ®Google Scholar
• Ryvlin P, Rheims S, Hirsch LJ, et al. Neuromodulation in epilepsy: state-of-the-art approved therapies. Lancet Neurol. 2021;20(12):1038–1047. doi: 10.1016/S1474-4422(21)00300-8
   PubMed Web of Science ®Google Scholar
• Chang C-H, Lane H-Y, Lin C-H. Brain stimulation in Alzheimer’s disease. Front Psychiatry. 2018;9:201. doi: 10.3389/fpsyt.2018.00201
   PubMed Web of Science ®Google Scholar
• Cantello R, Rossi S, Varrasi C, et al. Slow repetitive TMS for drug-resistant epilepsy: clinical and EEG findings of a placebo-controlled trial. Epilepsia. 2007;48(2):366–374. doi: 10.1111/j.1528-1167.2006.00938.x
   PubMed Web of Science ®Google Scholar
• Sudbrack-Oliveira P, Barbosa MZ, Thome-Souza S, et al. Transcranial direct current stimulation (tDCS) in the management of epilepsy: a systematic review. Seizure. 2021;86:85–95. doi: 10.1016/j.seizure.2021.01.020
   PubMed Web of Science ®Google Scholar
• Tsuboyama M, Kaye HL, Rotenberg A. Review of Transcranial Magnetic Stimulation in Epilepsy. Clin Ther. 2020;42(7):1155–1168. doi: 10.1016/j.clinthera.2020.05.016
   PubMed Web of Science ®Google Scholar
• Birba A, Ibáñez A, Sedeño L, et al. Non-invasive brain stimulation: A new strategy in mild cognitive impairment? Front Aging Neurosci [Internet]. 2017;9. [cited 2023 Sep 29]. Available from: http://journal.frontiersin.org/article/10.3389/fnagi.2017.00016/full doi: 10.3389/fnagi.2017.00016
   Google Scholar
• Hsu W-Y, Ku Y, Zanto TP, et al. Effects of noninvasive brain stimulation on cognitive function in healthy aging and Alzheimer’s disease: a systematic review and meta-analysis. Neurobiol Aging. 2015;36:2348–2359. doi: 10.1016/j.neurobiolaging.2015.04.016
   PubMed Web of Science ®Google Scholar
• Chou Y-H, Ton That V, Sundman M. A systematic review and meta-analysis of rTMS effects on cognitive enhancement in mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging. 2020;86:1–10. doi: 10.1016/j.neurobiolaging.2019.08.020
   PubMed Web of Science ®Google Scholar
• Yan Y, Tian M, Wang T, et al. Transcranial magnetic stimulation effects on cognitive enhancement in mild cognitive impairment and Alzheimer’s disease: a systematic review and meta-analysis. Front Neurol. 2023;14:1209205. doi: 10.3389/fneur.2023.1209205
   PubMed Web of Science ®Google Scholar
• Taylor JJ, Newberger NG, Stern AP, et al. Seizure risk with repetitive TMS: survey results from over a half-million treatment sessions. Brain Stimulation. 2021;14(4):965–973. doi: 10.1016/j.brs.2021.05.012
   PubMed Web of Science ®Google Scholar
• Teselink J, Bawa KK, Koo GK, et al. Efficacy of non-invasive brain stimulation on global cognition and neuropsychiatric symptoms in Alzheimer’s disease and mild cognitive impairment: a meta-analysis and systematic review. Ageing Res Rev. 2021;72:101499. doi: 10.1016/j.arr.2021.101499
   PubMed Web of Science ®Google Scholar
• Saleh O, Assaf M, Alzoubi A, et al. The effects of transcranial direct current stimulation on cognitive function for mild cognitive impairment: a systematic review and meta-analysis of randomized controlled trials. Aging Clin Exp Res. 2023. doi:10.1007/s40520-023-02528-2
   PubMed Web of Science ®Google Scholar
• Gomes-Osman J, Indahlastari A, Fried PJ, et al. Non-invasive brain stimulation: probing intracortical circuits and improving cognition in the Aging brain. Front Aging Neurosci. 2018;10:177. doi: 10.3389/fnagi.2018.00177
   PubMed Web of Science ®Google Scholar
• Gao J, Li L. Enhancement of neural regeneration as a therapeutic strategy for Alzheimer’s disease (review). Exp Ther Med. 2023;26(3):444. doi: 10.3892/etm.2023.12143
   PubMed Web of Science ®Google Scholar
• Senevirathne DKL, Mahboob A, Zhai K, et al. Deep brain stimulation beyond the clinic: navigating the future of Parkinson’s and Alzheimer’s disease therapy. Cells. 2023;12(11):1478. doi: 10.3390/cells12111478
   PubMed Web of Science ®Google Scholar
• Laxton AW, Tang-Wai DF, McAndrews MP, et al. A phase I trial of deep brain stimulation of memory circuits in Alzheimer’s disease. Ann Neurol. 2010;68(4):521–534. doi: 10.1002/ana.22089
   PubMed Web of Science ®Google Scholar
• Lozano AM, Fosdick L, Chakravarty MM, et al. A phase II study of fornix deep brain stimulation in mild Alzheimer’s disease. J Alzheimers Dis. 2016;54(2):777–787. doi: 10.3233/JAD-160017
   PubMed Web of Science ®Google Scholar
• Kuhn J, Hardenacke K, Lenartz D, et al. Deep brain stimulation of the nucleus basalis of Meynert in Alzheimer’s dementia. Mol Psychiatry. 2015;20(3):353–360. doi: 10.1038/mp.2014.32
   PubMed Web of Science ®Google Scholar
• Kuba R, Guzaninová M, Brázdil M, et al. Effect of vagal nerve stimulation on interictal epileptiform discharges: a scalp EEG study. Epilepsia. 2002;43(10):1181–1188. doi: 10.1046/j.1528-1157.2002.08202.x
   PubMed Web of Science ®Google Scholar
• Vargas-Caballero M, Warming H, Walker R, et al. Vagus nerve stimulation as a potential therapy in early Alzheimer’s disease: a review. Front Hum Neurosci. 2022;16:866434. doi: 10.3389/fnhum.2022.866434
   PubMed Web of Science ®Google Scholar
• Sjögren MJC, Hellström PTO, Jonsson MAG, et al. Cognition-enhancing effect of vagus nerve stimulation in patients with Alzheimer’s disease: a pilot study. J Clin Psychiatry. 2002;63(11):972–980. doi: 10.4088/JCP.v63n1103
   PubMed Web of Science ®Google Scholar
• Merrill CA, Jonsson MAG, Minthon L, et al. Vagus nerve stimulation in patients with Alzheimer’s disease: additional follow-up results of a pilot study through 1 year. J Clin Psychiatry. 2006;67(8):1171–1178. doi: 10.4088/JCP.v67n0801
   PubMed Web of Science ®Google Scholar
• Baker J, Libretto T, Henley W, et al. A Longitudinal Study of Epileptic Seizures in Alzheimer’s Disease. Front Neurol. 2019;10:1266. doi: 10.3389/fneur.2019.01266
   PubMed Web of Science ®Google Scholar
• Liu J, Wang L-N, Wu L-Y, et al. Treatment of epilepsy for people with Alzheimer’s disease. Cochrane epilepsy group, editor. Cochrane Database Syst Rev [Internet]. 2016. [cited 2023 Mar 18]. doi:10.1002/14651858.CD011922.pub2
   Web of Science ®Google Scholar
• Liu J, Wang L-N, Wu L-Y, et al. Treatment of epilepsy for people with Alzheimer’s disease. Cochrane Epilepsy Group, editor. Cochrane Database Syst Rev [Internet]. 2018. [cited 2023 Mar 18]. doi:10.1002/14651858.CD011922.pub3
   Web of Science ®Google Scholar
• Liu J, Wang L-N. Treatment of epilepsy for people with Alzheimer’s disease. Cochrane epilepsy group, editor. Cochrane Database Syst Rev [Internet]. 2021;2021(5). doi: 10.1002/14651858.CD011922.pub4
   Google Scholar
• Vöglein J, Ricard I, Noachtar S, et al. Seizures in Alzheimer’s disease are highly recurrent and associated with a poor disease course. J Neurol. 2020;267(10):2941–2948. doi: 10.1007/s00415-020-09937-7
   PubMed Web of Science ®Google Scholar